Nektar presented two presentations of NKTR-255 at ASH. NKTR-255 was well tolerated in heavily pre-treated patients with hematologic malignancies (NHL and MuMy) in doses up to 12 μg/kg and in combination with daratumumab in doses up to 9 μg/kg.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Nektar presented first positive Phase 1 data of NKTR-255 in multiple myeloma
CLINICAL AND REGULATORY
Nektar presented first data for NKTR-255 in combo with daratumumab in multiple myeloma
Nektar presented two presentations of NKTR-255 at ASH. NKTR-255 was well tolerated in heavily pre-treated patients with hematologic malignancies (NHL and MuMy) in doses up to 12 μg/kg and in combination with daratumumab in doses up to 9 μg/kg. The majority of treatment-related adverse events were low-grade, transient, and easily managed. The maximum tolerated dose was not reached. No new safety signals or overlapping toxicities were observed with the doublet and dose escalation is ongoing. Early evidence of clinical activity was observed in this heavily pre-treated and highly refractory patient population with the doublet (NKTR-255 + daratumumab). Additionally, Nektar revealed study design of an upcoming Phase 2/3, randomized, double-blind, placebo-controlled, multicenter clinical trial of NKTR-255 following CD19-directed CAR-T cell therapy in patients with relapsed/refractory large B-cell lymphoma.
DEALS AND FINANCING
ImmunityBio get $157 million financing as PDUFA date nears
With the PDUFA date for its lead bladder cancer treatment now only six months away, ImmunityBio raised $157 million, mostly from “Nant” entities affiliated with founder and Executive Chairman Patrick Soon-Shiong, via an equity financing from a single, undisclosed investor, a debt financing and conversion of about $57 million of debt held by NantWorks into ImmunityBio equity at $5.67 per share. ImmunityBio will receive another $60 million if a warrant is exercised. ImmunityBio’s shares rose 10% to $6.77. The company had $111 million cash on Sept. 30.
